OverviewChartNewsTraderScreen

Soc. Generale Knock-Out SNW/  DE000CL7G2W4  /

Frankfurt Zert./SG
2024-05-17  7:01:24 PM Chg.-0.040 Bid8:04:02 PM Ask8:04:02 PM Underlying Strike price Expiration date Option type
1.770EUR -2.21% 1.770
Bid Size: 2,000		 1.800
Ask Size: 2,000		 SANOFI SA INHABER ... 71.9947 - 2078-12-31 Call
GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
TeleTrader 05-13 Europe mixed at open as CPI prints loom
GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 05-10 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 05-10 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 05-10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 05-09 Europe opens mixed with BoE in focus
GlobeNewswire 05-08 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 05-02 Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire 04-30 Press Release: Annual General Meeting of April 30, 2024
TeleTrader 04-25 Europe opens mostly down after corporate earnings
TeleTrader 04-25 Europe down in premarket as financial results pour in
TeleTrader 04-25 Sanofi books net sales of €10.5B in Q1, up 2.4%
GlobeNewswire 04-25 Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire 04-23 Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
GlobeNewswire 04-17 IGM Biosciences Announces Refocusing of Sanofi Collaboration
GlobeNewswire 04-17 Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in ...
GlobeNewswire 04-16 2024 DTA Summit Agenda is LIVE!!
GlobeNewswire 04-10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 04-09 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targe...
GlobeNewswire 03-29 Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update